Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.60 |
| ▸ | TST | Q16762 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874725 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL15364 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL16950234 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL936066 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL875292 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL444603 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL1503121 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL16201 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL875399 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL | |
| SCHEMBL22730055 | 1.00 | MAPT (0.60) | MAPTHSPD1HSPE1TSTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. | 2021-07-01 | — | — | US | claimed |
| EP-3773478-A1 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF | Alivio Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-10881745-B2 | Formulation of nanostructured gels for increased agent loading and adhesion | Alivio Therapeutics, Inc. (US) | 2021-01-05 | — | — | US | claimed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | claimed |
| EP-3621594-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019195546-A1 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF | Alivio Therapeutics, Inc. (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190307885-A1 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF | Alivio Therapeutics, Inc. | 2019-10-10 | — | — | US | claimed |
| EP-3452014-A1 | SELF-ASSEMBLED GEL FOR CONTROLLED DELIVERY OF THERMOLABILE AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2018208822-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. (US) | 2018-11-15 | — | — | WO | claimed |
| US-20180318442-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | Alivio Therapeutics, Inc. | 2018-11-08 | — | — | US | claimed |
| US-20180318423-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCCAPSULATED AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | claimed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20170319500-A1 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND LABILE AGENTS | UNITED STATES GOVERNMENT | 2017-11-09 | — | — | US | claimed |
| WO-2017193138-A1 | SELF-ASSEMBLED GEL FOR CONTROLLED DELIVERY OF THERMOLABILE AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | claimed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | claimed |
| EP-2618821-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MAPT 2799/4885HSPD1 413/4885HSPE1 181/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MAPT 2799/4885HSPD1 413/4885HSPE1 181/4885 |
| US-20180318442-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | LTA, TMSB4X, TLN1 | MAPT 1557/4885HSPD1 1487/4885HSPE1 1712/4885 |
| US-20180318423-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCCAPSULATED AGENTS | ELANE, ENGASE, MMP2 | MAPT 2884/4885HSPD1 1002/4885HSPE1 530/4885 |
| US-10881745-B2 | Formulation of nanostructured gels for increased agent loading and adhesion | LTA, TMSB4X, TLN1 | MAPT 1557/4885HSPD1 1487/4885HSPE1 1712/4885 |
| US-20210196836-A1 | FORMULATION OF NANOSTRUCTURED GELS FOR INCREASED AGENT LOADING AND ADHESION | LTA, TMSB4X, TLN1 | MAPT 1557/4885HSPD1 1487/4885HSPE1 1712/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | MAPT 3008/4885HSPD1 519/4885HSPE1 234/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | MAPT 2799/4885HSPD1 413/4885HSPE1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.